CYTK Cytokinetics, Incorporated
$60.90▲ +0.28%
Healthcare
Other
Volume 60.9K
Avg Volume (10D) 1.48M
Key Metrics & Fundamentals
Market Cap
$8.47B
P/E Ratio
–
Div Yield
0.00%
52W Range
58.05 - 88.31
% vs 50 MA
-11.55%
% vs 200 MA
-13.38%
RSI-14
35.1
MACD Histogram
+0.2200
Beta (1Y vs SPY)
0.75
Free Cash Flow
-$164.17M
Gross Rev
$28.62M
Gross Profit
$23.03M
EBITDA
-$159.20M
COGS
$5.59M
Operating Exp
$202.20M
Operating Income
-$179.17M
EBIT
-$179.17M
Pretax Income
-$198.76M
Net Income
-$198.76M
EPS (Diluted)
-1.50
Price & Volume History
Loading chart…
Recent News
Cytokinetics to Announce Third Quarter Results on November 4, 2026
GlobeNewswire · Oct 21, 2026 4:00 PM ET
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
Business Wire · Oct 21, 2026 12:30 PM ET
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 19, 2026 4:00 PM ET
BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says
MT Newswires · Oct 19, 2026 11:42 AM ET
Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?
Zacks · Oct 19, 2026 8:40 AM ET
Cytokinetics Wins Health Canada Approval for Myqorzo Heart Drug
MT Newswires · Oct 19, 2026 8:34 AM ET
BofA Securities Adjusts Price Target on Cytokinetics to $81 From $85, Maintains Neutral Rating
MT Newswires · Oct 19, 2026 8:13 AM ET
Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
GlobeNewswire · Oct 19, 2026 7:30 AM ET
William Blair Initiates Coverage on Cytokinetics With Outperform Rating
MT Newswires · Oct 16, 2026 7:27 AM ET
Cytokinetics Sees Myqorzo Launch Strength Carry Into 2027, RBC Says
MT Newswires · Oct 15, 2026 11:21 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See CYTK's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.